ArticleThe journal of trauma and acute care surgery2025
Treatment with MG53 ameliorates traumatic brain injury-associated acute kidney injury.
Article in The journal of trauma and acute care surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- MG53 Coordinates Macrophage Polarization and Neuroimmune Coupling to Promote Corneal Nerve Regeneration via the MPEG1-MVP-STAT6 Axis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Decreased serum MG53 levels are associated with SHBG and androgen excess in women with polycystic ovary syndrome.Scientific reports · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
introductionMultiorgan dysfunction (MOD) after traumatic brain injury (TBI) results in increased morbidity and mortality. There is emerging evidence demonstrating TBI-induced inflammatory responses; however, the mechanisms driving TBI-induced organ injury remains unknown and understudied. MG53, a cell membrane repair protein, has been shown to reduce brain lesion size following TBI. In this study, we aimed to establish a large animal model of post-TBI MOD, determine MG53's role in renal protection following TBI, and explore a mechanistic link between endothelial cell dysfunction and post-TBI MOD.
methodsFemale Yorkshire swine (n = 5/group) were subjected to controlled cortical impact TBI and randomized to receive (1) MG53 protein therapy or (2) normal saline (control). Biomarkers of acute kidney injury were compared between the groups. Kidneys were analyzed for histologic evidence of acute injury. Top-down proteomics were performed on swine plasma at various times post-TBI.
resultsControl animals had a significant increase in creatinine from baseline by 6 hours post-TBI ( p = 0.007), which was attenuated in the MG53-treated animals ( p = 0.089). Control animals had a significant increase in plasma NGAL from baseline starting at 4 hours from baseline ( p = 0.014). Animals treated with MG53 had no change in serum NGAL from baseline ( p = 0.163). Histologic analysis showed protection of proximal tubular epithelial cell damage in animals treated with MG53. Proteoform data showed differential expression of apolipoprotein 1, fibrinogen β, and osteocalcin.
conclusionTraumatic brain injury can induce distant organ damage, possibly through endothelial cell dysfunction, and treatment with a cell membrane repair protein (MG53) can protect against this injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.